EFTA02397065.pdf

From: Steven Sinofsky Sent: Thursday, Novem er , : To: Jeffrey E. Subject: Re: Was at PA's Pitch@P=lace. He is doing a super good job. Srsly. On Nov 2, 2017, at=10:25 PM, jeffrey E. <jeevacati=n@gmail.com <mailto:jeevacation@gmail.com> wrote: thx On Thu, Nov 2, 2017 at 6:24 PM, Steven Sinofsky &I=; wrote: =div> Greetings Masha, I apologize for th= delay. I was at some events in in UK where I did not have connectivi=y. I have worked on a related portfolio company so=I will have to be a bit abstract on the specifics of this opportunity. = So please excuse these brief thoughts. Also, the only information I had wa= what was provided in your mail which was limited relative to any detailed a=alysis. • In general the challenge with glucose me=surement is the finger prick. Any device that relies on this will only be m=rginally better than any other device, whether or not there is software or a=slightly more convenient measuring device. This is a statement about the in=onvenience of a prick (and long term challenges) but also the medical chall=nges on relying on that point in time. • My sense is that going d=wn the path of an innovation, that still has a prick, but requires a level o= FDA approval is a difficult one to approach. • This is a very cr=wded space. There are a lot of apps, a lot of measuring devices, a lot of m=xtures of app and measuring devices. It is very difficult to avoid appearin= as a commodity to consumers. • While I understand there is poten=ial to see innovation using novel approaches to analysis of data, it is not=clear to me how much better the approach can be for an individual with data= • The real opportunity I might see is around measuring glucose o= some related telemetry to assist in compliance that is outside the scope o= a finger prick and measuring glucose directly. It seems like we should hav= some other data point upon which to apply machine learning. =/div> I hope this helps...any friend of JE is a friend of mine. On Nov 1, 2017, at 4:43 PM, Masha Drokova wrote: EFTA_R1_01429961 EFTA02397065  Thank you Jeffrey= Steve, great meeting you. Would appreciate your feedback&n=sp; On Nov 1, 2017, at 9:31 AM, Jeffrey E. <jeevacation@gmail.com> w=ote: steve can=you give some guidance • Center Health is building an A=-based glucose monitoring system for the 1 in 11 Americans who suffer f=om diabetes, based on machine learning and their personalized Al, Aria= Users subscribe to their disposable test strips, a $14 Wyr US market, whic= are delivered monthly, as Aria learns about their diabetes and prompts beh=vioral changes to lower blood sugar. The system is an order of ma=nitude cheaper than existing technologies, premised on leveraging data to h=lp users see what daily elements are affecting their blood sugar, and p=edicting dangerous highs and lows before they happen. </=iv> Pros — Existing glucometers from big companies=are very old-fashioned and outdated, those companies make their revenue fro= overpriced strips — Direct competitors, such as =/span>iHealth and Dario have negative customer reviews and minor —&=bsp;Uses FDA-approved circuits to get the approval in an automated manner</=ont> =i>Cons — Enormous pr=ssure both from the industry players and companies such as Apple and Google=that try to develop non-invasive glucose monitoring that will wipe out test=strip products <=ont face="Roboto-Regular">— Hardware startup without a product to=sell yet, finalizing the development — Young team = &=bsp; please note The information contained in this communicat=on is confidential, may be attorney-client privileged, may constitute=inside information, and is intended only for the use of the addressee. 1= is the property of JEE Unauthorized use, disclosure or copying of th=s 2 EFTA_R1_01429962 EFTA02397066  communication or any part thereof is strictly prohibited and may be=unlawful. If you have received this communication in error, please notif= us immediately by return e-mail or by e-mail to jeevacation@gmail.com <mailtoleeva=ation@gmail.com> , and destro= this communication and all copies thereof, including all attachments. c=pyright -all rights reserved please=note The information contained in this communication is confiden=ial, may be attorney-client privileged, may constitute inside informatio=, and is intended only for the use of the addressee. It is the property o= JEE Unauthorized use, disclosure or copying of this communication=or any part thereof is strictly prohibited and may be unlawful. If you h=ve received this communication in error, please notify us immediately by=br>return e-mail or by e-mail to jeevacation@gmail.com <mailto:jeevacation@gmail.com> , and destroy this communicatio= and all copies thereof, including all attachments. copyright -all right= reserved 3 EFTA_R1_01429963 EFTA02397067